We are live on ! Find out more
VPC

Vestal Point Capital Portfolio holdings

AUM $3.58B
1-Year Est. Return 189.12%
This Fund
S&P 500
This Quarter Est. Return
+63.68%
1 Year Est. Return
+189.12%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.94B
AUM Growth
+$727M
Cap. Flow
+$234M
Cap. Flow %
7.95%
Top 10 Hldgs %
50.17%
Holding
105
New
24
Increased
24
Reduced
21
Closed
29

Top Buys

Rank Stock Value
1
ACLX
Arcellx
ACLX
+$134M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$118M
3
TERN
Terns Pharmaceuticals
TERN
+$104M
4
ABVX
Abivax
ABVX
+$98.2M
5
MRK icon
Merck
MRK
+$72.7M

Top Sells

Rank Stock Value
1
NUVL
Nuvalent
NUVL
+$104M
2
ASND icon
Ascendis Pharma A/S
ASND
+$87.8M
3
FOLD
Amicus Therapeutics
FOLD
+$76.8M
4
IONS icon
Ionis Pharmaceuticals
IONS
+$70.3M
5
BDX icon
Becton Dickinson
BDX
+$60.8M

Sector Composition

Rank Sector Weight
1 Healthcare 92.69%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AGIO icon
51
Agios Pharmaceuticals
AGIO
$1.93B
$8.85M 0.3%
325,000
+198,000
+156% +$6.95M
DFTX
52
Definium Therapeutics
DFTX
$6.07B
$8.53M 0.29%
+637,000
New +$7.88M
DNLI icon
53
Denali Therapeutics
DNLI
$3.93B
$7.68M 0.26%
+465,000
New +$7.85M
MYGN icon
54
Myriad Genetics
MYGN
$315M
$7.52M 0.26%
1,223,000
+623,000
+104% +$4.52M
TECX
55
Tectonic Therapeutic
TECX
$579M
$6.84M 0.23%
+328,000
New +$6.1M
NVCR icon
56
NovoCure
NVCR
$1.91B
$6.79M 0.23%
525,000
+125,000
+31% +$1.6M
MPLT
57
MapLight Therapeutics
MPLT
$557M
$6.76M 0.23%
+385,000
New +$6.45M
GILD icon
58
Gilead Sciences
GILD
$166B
$6.14M 0.21%
+50,000
New +$6.08M
VYGR icon
59
Voyager Therapeutics
VYGR
$198M
$5.8M 0.2%
1,475,000
– –
DBVT
60
DBV Technologies
DBVT
$852M
$5.75M 0.2%
+300,000
New +$4.69M
MIRM icon
61
Mirum Pharmaceuticals
MIRM
$6.18B
$5.21M 0.18%
+66,000
New +$4.74M
NYXH
62
Nyxoah
NYXH
$144M
$5.09M 0.17%
1,107,000
-413
-0% -$2.13K
NUVL
63
DELISTED
Nuvalent
NUVL
$4.63M 0.16%
46,000
-1,054,000
-96% -$104M
LENZ
64
LENZ Therapeutics
LENZ
$168M
$4.4M 0.15%
+275,000
New +$8.02M
RZLT icon
65
Rezolute
RZLT
$450M
$3.98M 0.14%
+1,686,000
New +$13.2M
PASG icon
66
Passage Bio
PASG
$14.1M
$3.6M 0.12%
305,000
– –
STRO icon
67
Sutro Biopharma
STRO
$422M
$2.81M 0.1%
243,000
-17,000
-7% -$161K
GPCR icon
68
Structure Therapeutics
GPCR
$3.78B
$2.43M 0.08%
+35,000
New +$1.43M
DYN icon
69
Dyne Therapeutics
DYN
$4.9B
$2.35M 0.08%
120,000
-2,655,000
-96% -$50.3M
BDTX icon
70
Black Diamond Therapeutics
BDTX
$113M
$2.11M 0.07%
870,000
-4,680,000
-84% -$16.6M
OKUR
71
OnKure Therapeutics
OKUR
$167M
$1.84M 0.06%
635,000
– –
FATE icon
72
Fate Therapeutics
FATE
$325M
$1.69M 0.06%
1,725,000
-790,000
-31% -$949K
ALEC icon
73
Alector
ALEC
$199M
$1.18M 0.04%
755,000
-225,000
-23% -$399K
TENX icon
74
Tenax Therapeutics
TENX
$510M
$651K 0.02%
53,439
– –
RGNX icon
75
Regenxbio
RGNX
$710M
$490K 0.02%
+34,000
New +$424K
1 2
3
4 5

Similar funds

WWA
WCG Wealth Advisors Las Vegas, Nevada $3.57B AUM 18.63% 1-Year Est. Return
BPS
BNDES Participacoes SA Rio De Janeiro, Brazil $3.58B AUM
U
Uber San Francisco, California $3.6B AUM 19.81% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $3.54B AUM 19.14% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return
ACM
Advent Capital Management New York $3.63B AUM 0.29% 1-Year Est. Return
TYCC
Texas Yale Capital Corp St. Petersburg, Florida $3.52B AUM 52.63% 1-Year Est. Return

Vestal Point Capital's Q4 2025 Portfolio in Review

As of Q4 2025, Vestal Point Capital held 105 positions worth $2.94B, up 33% from $2.21B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Vestal Point Capital deployed $234M of net new capital in Q4 2025, opening 24 new positions and adding to 24 existing holdings. Its largest new stake was Terns Pharmaceuticals: 4,500,000 shares worth $182M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 100% a quarter earlier.

On the sell side, the largest reduction was Nuvalent, an estimated $104M trimmed.

  • Vestal Point Capital's largest Q4 2025 buy was Terns Pharmaceuticals: 4,500,000 shares worth $182M.
  • Vestal Point Capital added most to Arcellx in Q4 2025, an estimated $134M increase.
  • Vestal Point Capital's biggest Q4 2025 reduction was Nuvalent, cutting an estimated $104M.
  • Vestal Point Capital fully exited Amicus Therapeutics in Q4 2025, selling an estimated $76.8M.
  • Vestal Point Capital's ten largest holdings make up 50% of its $2.94B portfolio in Q4 2025.
  • Vestal Point Capital opened 24 new positions and closed 29 in Q4 2025.
  • Vestal Point Capital's portfolio value rose 33% quarter-over-quarter to $2.94B.

Based on Vestal Point Capital's 13F filing for Q4 2025, filed 17 Feb 2026.